ORIC Pharmaceuticals

Phase 1b data for rinzimetostat + darolutamide in mCRPC highlight potential best-in-disease profile, supporting advancement into Phase 3. Join our webcast at 4:30 p.m. ET today for a detailed review & program update: bit.ly/3VxP4tj Press release:lnkd.in/gY7wSVtB

We are pleased to share that two preclinical abstracts reinforcing the best-in-class potential of rinzimetostat (ORIC-944) to treat prostate cancer have been accepted for poster presentation at #AACR2026 taking place April 17-22, 2026. Learn more here: bit.ly/40CeXx6

Happy #EmployeeAppreciationDay to our incredible team! From team activities to recognition and wellness initiatives, we’re celebrating the people who power our mission to Overcome Resistance In Cancer every day. Thank you for all you do.

This #InternationalWomensDay, we honor the women powering our mission to Overcome Resistance In Cancer. Aligned with #GiveToGain, we know that when we invest in women, we strengthen science and outcomes for patients. When women thrive, we all rise. #WomenInBiotech #IWD2026

2025 was a year of meaningful progress across our clinical pipeline. We advanced 2 clinical programs with data highlighting differentiated efficacy & safety, building momentum toward potential registrational studies and key milestones ahead. bit.ly/4aPvOBc

$ORIC CFO @Dom_Piscitelli & CBO @mattpanuwat will participate in a fireside chat at @Oppenheimer’s 36th Annual Healthcare Life Sciences conference on Wed, Feb 25, 2026, at 12:00 p.m. ET. Listen to the discussion to learn the latest company updates here: bit.ly/3VxP4tj

Prevention, early detection, and research all play a critical role in the fight against cancer. This #CancerPreventionMonth, we’re reminded that progress begins long before diagnosis and continues through science. #EarlyDetection #ScienceMatters

Welcoming the Lunar New Year and the Year of the Fire Horse, a period of high energy, rapid progress, and passionate, independent action. Wishing our global community a year of health, renewal, and continued progress through science. #LunarNewYear #YearOfTheFireHorse

$ORIC President & CEO, @JacobChackoMD and CFO @Dom_Piscitelli will participate in a fireside chat at @Citi’s 2026 Virtual Oncology Leadership Summit on Wednesday, February 18, 2026, at 2:30 p.m. ET. Listen to the live or archived discussion here: bit.ly/3VxP4tj

Today we celebrate the women and girls driving scientific discovery forward. Advocating for equity and opportunity in STEM strengthens and accelerates innovation for patients everywhere. #WomenInScience #GirlsInSTEM #IDWGS

$ORIC CFO @Dom_Piscitelli & CBO @mattpanuwat will participate in a fireside chat at @Guggenheim’s Emerging Outlook: Biotech Summit on Thurs, Feb 12, 2026, at 10:30 a.m. ET. Listen to the discussion to learn the latest company updates here: bit.ly/3VxP4tj

Behind every cancer diagnosis is a unique human story. This #WorldCancerDay, we stand #UnitedByUnique, advocating for people-centered cancer care that combines scientific innovation with compassion and empathy for every patient.

This #MLKDay, we honor Dr. King’s legacy & call for equity & opportunity. Diversity of thought & experience strengthens science & fuels innovation. At ORIC®, inclusion & respect are core values. We’re committed to fostering an environment where everyone feels welcome & respected.

We ended 2025 with strong momentum, reporting compelling data across rinzimetostat (ORIC-944) and enozertinib programs. As we approach 2 potential registrational studies & meaningful data milestones, we’re excited for the progress and possibilities ahead. bit.ly/3Nd9RE5

$ORIC President & CEO, @JacobChackoMD will kick-off 2026 at the 44th Annual @JPMorgan Healthcare Conference. Listen to the presentation live on Tuesday, January 13, 2026, at 9:45 a.m. PT, or the archived replay here: bit.ly/3VxP4tj #JPM2026

We’re pleased to announce that our potential best-in-class PRC2 inhibitor ORIC-944 is now rinzimetostat! This marks an important step as we advance our mission to overcome resistance in cancer and bring new options to patients with prostate cancer.

Here’s to a new year of progress and purpose. In 2026, we remain committed to advancing therapies to Overcome Resistance In Cancer and bringing new hope to patients. Grateful for everyone who supports this mission. #NewYear #Biotech #CancerResearch #Innovation

Happy Holidays from all of us at ORIC! We’re grateful for the patients, physicians, partners & colleagues who inspire our mission to Overcome Resistance In Cancer. Wishing everyone a peaceful and joyful season. #HappyHolidays #CancerResearch

Our HR team served up lattes, pastries, and plenty of smiles at our 3rd annual Café De ORIC Event! This tradition is one of our favorites and a simple way to connect, recharge, and celebrate the people who make our workplace so special. Cheers to community and culture!

We presented compelling Phase 1b data for enozertinib (ORIC-114) at #ESMOAsia2025. Results in EGFR exon 20 and EGFR PACC mutated NSCLC show impressive systemic + intracranial activity and a favorable safety profile. Join our webcast at 8 p.m. ET. bit.ly/3VxP4tj